NeuroSigma has announced that it will be presenting its CE-marked Monarch trigeminal nerve stimulation system (eTNS) for the adjunctive treatment of epilepsy and depression at the 10th European Congress on Epileptology (London, UK, 30 September to 4 October 2012).
On 30 September, the company will lead a Satellite Symposium focused on trigeminal nerve stimulation for the treatment of epilepsy and neuropsychiatric disorders.
The presentations will cover:
- Trigeminal nerve stimulation background science
- Clinical trials of eTNS for drug resistant epilepsy, including the first public presentation of long-term data on the efficacy of eTNS for the treatment of epilepsy
- Clinical trials of eTNS for depression and PTSD
- Monarch eTNS product launch in the European Union
Presenters in the Satellite Symposium are: Christopher DeGiorgio, vice-president, NeuroSigma, and professor of Neurology at University of California, Los Angeles (UCLA); Ian Cook, senior medical advisor, NeuroSigma, and professor of Psychiatry at UCLA and Colin Kealey, manager of Business Development, NeuroSigma.
DeGiorgio will also participate in an additional panel discussion: Devices and Epilepsy: the future, on Wednesday 3 October.
NeuroSigma also announced that it is preparing for a fourth quarter 2012 commercial launch of the Monarch in the European Union.
In the United States, the Monarch eTNS is an investigational device.
Trigeminal nerve stimulation was invented at UCLA and is exclusively licensed to NeuroSigma.
